Category Archives: BioInformatics

Szilak Lab Bioinformatics and Molecule Design, HUNGARY (MIT-LS 2014) Szilak Laboratories Bioinformatics an Molecule-design Ltd MIT-LS 2014 Pitch Presentation - March 31, 2014 Szilak Laboratories Bioinformatics an Molecule-desi... By: Meet in Italy for Life Siences … Continue reading →

Sequenom Chief Medical Officer Allan Bombard plans to retire in June, the company said in a filing with the US Securities and Exchange Commission this week. Bombard has served as the firm's CMO since early 2009, and as one of its CLIA/CAP lab directors since 2010. Keygene's board of directors has appointed Fayaz Khazi as its new CEO, effective May 5. Khazi recently was VP of business analytics and strategy at Intrexon, where he worked since 2007 in various leadership positions focused on the food and agricultural sectors. He also was a Howard Hughes Medical Institute post-doctoral fellow at The Children's Hospital of Philadelphia and the University of Pennsylvania. Ryan Taft has joined Illumina as director of scientific research. Taft is laboratory head and senior research fellow at the University of Queensland's Institute for Molecular Bioscience. He holds a BSc in biochemistry and molecular biology from the University of California, Davis. Taft will maintain a joint appointment with UQ while working for Illumina. Vermillion has tapped its James LaFrance, chairman of the firms' board of directors, to succeed Thomas McLain as president and CEO. LaFrance, who will continue to serve as Vermillion's board chairman, formerly was CEO of Omnyx, and … Continue reading →

Eagle, the Cambridge UK bioinformatics specialist, has won a Small Business Research Initiative (SBRI) competition which will see the company further develop its technology for genomic data management and analysis. As a winner of the first phase, Eagle will receive a share of the 1.6 million fund available. This will be used to extend the capabilities of its existing technology platform Eagle Core, which has been developed to meet the demand for improved NGS technology in the healthcare sector. The extensions include improved study tracking and data sharing, streamlined sequence analysis, variant calling and annotation pipelines in order to scale up for the 100,000 genomes analysis. This will also improve data protection and security compliance in line with NHS Information Governance and HIPAA. After the completion of the initial six-month project, a further 8 million will be made available in phase 2 of the competition to those companies judged to have the best products once they have been developed and tested. Eagle CEO Abel Ureta-Vidal said: Improved and streamlined genomic analysis will play a key role in tackling rare diseases and cancer. In both cases, the causes are a combination of genetic and other factors, making the need for improved … Continue reading →

Bioinformatics Software Carpentry Bootcamp - Session 4 By: Res Baz … Continue reading →

Dr. Jessica Schlueter Discusses Bioinformatics Research By: Mark Nunn … Continue reading →

Introduction to Bioinformatics Presenter By: ISQuaEducation … Continue reading →

Sequenom Chief Medical Officer Allan Bombard plans to retire in June, the company said in a filing with the US Securities and Exchange Commission this week. Bombard has served as the firm's CMO since early 2009, and as one of its CLIA/CAP lab directors since 2010. Keygene's board of directors has appointed Fayaz Khazi as its new CEO, effective May 5. Khazi recently was VP of business analytics and strategy at Intrexon, where he worked since 2007 in various leadership positions focused on the food and agricultural sectors. He also was a Howard Hughes Medical Institute post-doctoral fellow at The Children's Hospital of Philadelphia and the University of Pennsylvania. Ryan Taft has joined Illumina as director of scientific research. Taft is laboratory head and senior research fellow at the University of Queensland's Institute for Molecular Bioscience. He holds a BSc in biochemistry and molecular biology from the University of California, Davis. Taft will maintain a joint appointment with UQ while working for Illumina. Vermillion has tapped its James LaFrance, chairman of the firms' board of directors, to succeed Thomas McLain as president and CEO. LaFrance, who will continue to serve as Vermillion's board chairman, formerly was CEO of Omnyx, and … Continue reading →

PUBLIC RELEASE DATE: 8-May-2014 Contact: Sonia Furtado Neves pressoffice@embl.de 49-622-138-78263 European Molecular Biology Laboratory Hinxton, 8 May 2014 Researchers at the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute have discovered that some immune cells turn themselves off by producing a steroid. The findings, published in Cell Reports, have implications for the study of cancers, autoimmune diseases and parasitic infections. If you've ever used a steroid, for example cortisone cream on eczema, you'll have seen first-hand how efficient steroids are at suppressing the immune response. Normally, when your body senses that immune cells have finished their job, it produces steroids but which cells actually do that? In this latest study, scientists looked at Th2 immune cells during parasitic infection and saw that at a certain point, these cells produce a steroid called pregnenolone. "We were really surprised to see that these immune cells are producing a steroid. In cell culture, we see that the steroids play a part in regulating T cell proliferation," says Bidesh Mahata in the Teichmann group at EMBL-EBI and Sanger, who designed the study. "We had already seen that T-helper cells were producing steroids, but initially we were blind what was going on?" "Because … Continue reading →

Growing at an average rate of about 20%, India's biotech industry comprising of bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics may reach the $7 billion mark by the end of FY15, an industry body said in a study. "The biotechnology industry in India, comprising of about 400 companies has grown three-fold in the last five years to reach $4 billion in FY13," according to a study -- 'Access to Healthcare: Indian Perspective', conducted by The Associated Chambers of Commerce and Industry of India (Assocham). India's biotechnology sector is divided into five segments based on products and services offered - biopharmaceuticals, bioservices, bioagriculture, bioindustry and bioinformatics. "Biopharma is the largest sector contributing about 62% of the total revenue followed by bioservices (18%), bioagri (15%), bio-industry (4%), while bioinformatics is still at a nascent stage contributing just about 1% of the total revenue." With revenue generation to the tune of over Rs 12,600 crore, the bio-pharma sector comprises of vaccines, therapeutics and diagnostics. While, India has emerged as a leading destination for clinical trials, contract research and manufacturing activities owing to the growth in the bio services sector, which accounts for revenue generation worth about Rs 3,800 crore. "India's biotechnology sector is benefitting … Continue reading →

Mumbai, May 6: Growing at an average rate of about 20 per cent, Indias biotech industry comprising biopharmaceuticals, bioservices, bioagriculture, bioindustry and bioinformatics could reach the $7-billion mark by FY15. The biotechnology industry in India, comprising about 400 companies, has grown three-fold in the last five years to reach $4 billion in FY13, a study conducted by Assocham said. Biopharma is the largest sector contributing about 62 per cent of the total revenue followed by bioservices (18 per cent), bioagri (15 per cent), bioindustry (four per cent), while bioinformatics is still at a nascent stage contributing just about one per cent of the total revenue, it said. With revenue generation to the tune of over Rs 12,600 crore, the biopharma sector comprises vaccines, therapeutics and diagnostics. India has emerged as a leading destination for clinical trials, contract research and manufacturing activities owing to the growth in the bioservices sector, which accounts for revenue generation worth about Rs 3,800 crore. "Increasing investments, outsourcing activities and exports are the key drivers for growth in Indias biotech sector,'' said DS Rawat, Secretary General of Assocham. ``Biotechnology is a capital intensive sector with a long gestation period for returns. Hence, it is important to … Continue reading →